相关实验视频
Updated: May 12, 2026

11:19
Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
17.4K
[翻译文章]高风险儿科药物:通过跨学科共识技术的列表提案
Yolanda Hernández Gago1, Pedro J Alcalá Minagorre2, Belén Rodríguez Marrodán3
1Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Las Palmas, Spain.
概括
为儿童医院使用,制定了101种高风险药物 (HRM) 的共识清单. 该工具旨在提高所有儿童的药物安全性,包括那些体重过重的儿童.
科学领域:
- 儿科药理学 儿科药理学
- 药物的安全性 药物的安全性
- 医院药房 医院药房 医院药房
背景情况:
- 儿科患者面临更高的药物错误和伤害的风险.
- 识别高风险药物 (HRM) 对于提高儿科患者安全至关重要.
- 体重过重的儿童 (EBW) 是一个需要特别注意的脆弱子组.
研究的目的:
- 创建一个更新的,操作的HRM名单,用于医院使用在两岁以上的儿童.
- 通过儿科医生和医院药剂师之间的跨学科合作,在HRM上达成共识.
- 支持儿童药物管理中的安全改进策略.
主要方法:
- 采用了两阶段的方法:最初的文献审查,然后是双轮的Delphi方法.
- 一个由儿科医生和医院药剂师组成的跨学科小组参与了协商一致的过程.
- 结果被验证使用统计措施,如修改的卡帕统计.
主要成果:
- 最初的审查确定了26种药物类别和96种药物.
- 建立了101个HRM的最终共识清单,涵盖24个药理类.
- 高水平的专家间协议 (94.9%) 是通过德尔菲方法实现的.
结论:
- 编制的清单是未来研究和干预的宝贵工具.
- 它旨在提高一般儿科患者的药物安全性.
- 该清单对于高风险的儿科亚组特别重要,例如那些患有EBW.
相关概念视频
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

